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Low- and middle-income countriesObjective: This study evaluates the cost-effectiveness of maternal acellular pertussis (aP) immunization
in low- and middle-income countries using a dynamic transmission model.
Methods: We developed a dynamic transmission model to simulate the impact of infant vaccination with
whole-cell pertussis (wP) vaccine with and without maternal aP immunization. The model was calibrated
to Brazilian surveillance data and then used to project health outcomes and costs under alternative
strategies in Brazil, and, after adjusting model parameter values to reflect their conditions, in Nigeria
and Bangladesh. The primary measure of cost-effectiveness is incremental cost (2014 USD) per
disability-adjusted life-year (DALY).
Results: The dynamic model shows that maternal aP immunization would be cost-effective in Brazil, a
middle-income country, under the base-case assumptions, but would be very expensive at infant vacci-
nation coverage in and above the threshold range necessary to eliminate the disease (90–95%). At 2007
infant coverage (DTP1 90%, DTP3 61% at 1 year of age), maternal immunization would cost < $4,000 per
DALY averted. At high infant coverage, such as Brazil in 1996 (DTP1 94%, DTP3 74% at 1 year), cost/DALY
increases to $1.27 million. When the model’s time horizon was extended from 2030 to 2100, cost/DALY
increased under both infant coverage levels, but more steeply with high coverage. The results were mod-
erately sensitive to discount rate, maternal vaccine price, and maternal aP coverage and were robust
using the 100 best-fitting parameter sets. Scenarios representing low-income countries showed that
maternal aP immunization could be cost-saving in countries with low infant coverage, such as Nigeria,
but very expensive in countries, such as Bangladesh, with high infant coverage.
Conclusion: A dynamic model, which captures the herd immunity benefits of pertussis vaccination, shows
that, in low- and middle-income countries, maternal aP immunization is cost-effective when infant vac-
cination coverage is moderate, even cost-saving when it is low, but not cost-effective when coverage
levels pass 90–95%.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under theCCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Pertussis vaccine has been administered for decades worldwide,
although heterogeneity in coverage and delays in achieving cover-age have also been reported [1,2]. Yet, despite reportedly high
infant vaccination coverage, and in addition to its natural cyclical
nature, with peaks in disease every 3 to 5 years, resurgent pertussis
has been reported in many countries, especially among young
infants. Single-dose maternal acellular pertussis (aP) immuniza-
tion during pregnancy, which confers immunity on the infant
through transplacental antibody transfer and reduces infants’
exposure to the pathogen by protecting their mothers, could
S.-Y. Kim et al. Vaccine 39 (2021) 147–157efficiently prevent disease and death, particularly in infants in low-
and middle-income countries (LMICs) [3]. Although the period of
immunity conferred by transplacental antibody transfer is short,
perhaps 6 months at most [4], maternal aP immunization has the
potential to prevent pertussis in infants who are too young to be
vaccinated. Based on the potential benefits, theWorld Health Orga-
nization recommended that countries consider implementation of
maternal pertussis immunization [5].
As of 2018, sixteen countries, have implemented maternal aP
immunization. The majority is high-income, and five middle-
income countries (Argentina, Brazil, Colombia, El Salvador, and
Mexico) have incorporated maternal aP immunization into their
routine vaccination schedules [6]. No low-income countries have
done so, although these countries’ existing maternal immunization
programs, which already provide tetanus toxoid, offer a platform
with untapped potential to provide maternal aP immunization,
although at additional cost.
The purpose of this study is to evaluate the cost-effectiveness of
maternal aP immunization in LMICs, from the healthcare system
perspective, using a dynamic transmission model. To build the
model we drew on the rich data systems available in Brazil, a
middle-income country. The goal is to provide insights into the
cost-effectiveness profile of maternal immunization over time in
LMICs in order to help policymakers identify best strategies for
pertussis control. For comparability with other interventions for
low- and middle-income settings, we have measured health out-
comes in terms of disability-adjusted life years (DALYs).2. Methods
To capture the dynamics of pertussis epidemiology, we devel-
oped an age-stratified dynamic transmission model and fitted the
model to reported cases of pertussis in Brazil for the period
1999–2016. Using the model, we projected health and cost out-
comes of two strategies: infant whole-cell pertussis (wP) vaccina-
tion only, and infant wP vaccination plus maternal aP
immunization, from 2017 to 2030. Based on the model outcomes,
we estimated the cost-effectiveness of adding maternal aP immu-
nization to infant wP vaccination in terms of incremental cost per
DALY averted. In developing the dynamic transmission model, we
followed the recommendations of the ISPOR-SMDM Modeling
Good Research Practices Task Force Working Group on dynamic
transmission modeling [7].
The dynamic model was based on the rich data sources avail-
able for Brazil: surveillance, mortality and births, hospitalizations,
and immunization. In Brazil, infant wP vaccine was first introduced
into the routine immunization program in 1973 and is still used. A
pertussis epidemic began in 2011 and peaked in 2014 with more
than 8,000 reported cases. Maternal aP immunization was intro-
duced in late 2014, the peak year, as a response to the resurgent
pertussis burden. However, annual maternal aP coverages since
implementation (10.9% in 2014, 48.4% in 2015, and 33.8% in
2016) are low and thus the impact on pertussis epidemiology of
adding maternal immunization to the existing infant vaccination
schedule is not expected to be significant.2.1. Model structure
To model the epidemiological states and transmission dynamics
of pertussis in the entire Brazilian population, we developed a
dynamic transmission model in the form of a deterministic com-
partmental model, including S(=Susceptible), I(=Infected/Infec-
tious), and R(=Recovered) states. Given the uncertainty
surrounding the epidemiology and natural history of pertussis, in
order to identify a model structure that best fits the Brazilian data,148four model variants were tested, each with different assumptions
about immunity waning and repeat infections, building upon the
examples of a recent pertussis dynamic modeling study [8] (see
Appendix 1 for the model schematic of each variant and
equations).
Model 1 (SIR): Assumes lifelong immunity for both vaccination
and natural infection.
Model 2 (SIRS): Assumes immunity wanes and repeat infections
occur with the same reporting rate as primary infections.
Model 3 (SIRS2I2): Assumes immunity wanes and repeat infec-
tions occur with a lower reporting rate and less severity.
Model 4 ðSIRB2I2Þ: Assumes immunity wanes, repeat infections
are less likely to be reported, and susceptible individuals who
have previously been infected or vaccinated may experience
immunity boosting upon re-exposure.
The models included a V(=Vaccinated/Immune) state to simu-
late the impact of alternative pertussis vaccination strategies. The
V state distinguished immunity due to routine infant or maternal
pertussis vaccination and by dose up to three.
The dynamic model includes the entire population and is age-
structured with 18 age groups (0–1 month, 2–3, 4–5, 6–8, 9–11,
12–23 months, 2–4 years, and 5–9, 10–14, 15–19, 20–29, 30–39,
40–49, 50–59, 60–69, 70–79 and 80 + years). The first year of age
was subdivided into 5 groups to capture the impact of alternative
pertussis vaccination schedules on pertussis outcomes among
infants, the group with the highest pertussis disease burden.
Within the dynamic model, each age group has a different contact
rate with other age groups and age-group-specific transmission
probabilities per contact. This allows the model to reflect the trans-
mission dynamics of pertussis infection in the entire population,
calculating the force of infection (the rate at which susceptible
individuals become infected) as a function of the number of indi-
viduals infected over time.
The fact that pertussis cases (especially outpatient cases) are
significantly under-reported has to be taken into consideration
and the force of infection adjusted for under-reporting. Therefore,
the model explicitly incorporated a reporting rate parameter.
Initial conditions of each compartment in each variant of the
model were estimated based on the reporting rate, historical data
on reported pertussis cases, vaccination coverage rates, and mor-
tality and births. Appendix 2 provides more details about the esti-
mation process for the initial conditions.
2.2. Model inputs
Table 1 presents the key model inputs. Pertussis disease burden
data were obtained from various sources. Pertussis deaths were
obtained from the Brazilian mortality system (Sistema de Infor-
mação sobre Mortalidade, SIM). We assumed that all deaths are
reported (no under-reporting) and thus we used the data as
reported by the mortality system. Inpatient pertussis cases hospi-
talized in the public health system were obtained from the public
health system (SUS) hospitalization information system (Sistema
de Informações Hospitalares, SIH-SUS). Like the deaths, we assumed
that, due to their severity, all hospitalized pertussis cases are
reported but we adjusted the number of hospitalized cases
reported to SIH-SUS in each Brazilian state by the state’s SUS cov-
erage rate, on the assumption that the reporting rate in the private
system was the same. We used pertussis cases reported to the
National Notifiable Diseases Surveillance Information System (Sis-
tema de Informação de Agravos de Notificação, SINAN), taking con-
firmed cases (by laboratory, clinical, or epidemiological
confirmation criteria) to represent the total number of symp-
tomatic cases (outpatient cases, hospitalizations, and deaths).
Table 1
Key model inputs.
Symbol Description Value (Range) Source
Natural history parameters
k force of infection c  q Estimated within model
c contact rate See Appendix 3 Determined through calibration
q transmission probability per contact See Appendix 3 Determined through calibration
c recovery rate 1/21 days Heymann (2004)
q1 reporting rate among I1 0y: 8.3%, 1-9y: 7.1%, 10y+: 6.2% Determined through calibration
q2 reporting rate among I2 (multiplier relative
to I1 reporting rate)
0.4 Determined through calibration
lp pertussis specific mortality Brazil data
Vaccine characteristics
mC1 wP vaccine coverage (1st dose) 90% (2007), 94% (1996) Brazil data
mC2 wP vaccine coverage (2nd dose) 79% (2007), 88% (1996) Brazil data
mC3 wP vaccine coverage (3rd dose) 61% (2007), 74% (1996) Brazil data
vM maternal aP vaccine coverage 10.9% (2014) to 70% (2030) Brazil data
hC rate of wP vaccine failure 0.1 (0–0.15) Magpantay (2016)
gC1 wP effectiveness (1st dose) 0.68 (95% CI: 0.456–0.811) Juretzko (2002)
gC2 wP effectiveness (2nd dose) 0.92 (95% CI: 0.847–0.957) Juretzko (2002)
gC3 wP effectiveness (3rd dose) 0.99 (95% CI: 0.989–1.000) Juretzko (2002)
hM rate of maternal vaccine failure 0.1 (0–0.50) Bento (2016)
gM maternal aP effectiveness 0.91 (95% CI: 0.84–0.95) Amirthalingam (2014)
rv duration of wP immunity 7.309 years (5–30 years) Determined through calibration
rM duration of maternal aP immunity 3 months (2–6 months) Van Rie (2005), Smallenburg (2014), Bento (2016)
rR duration of natural immunity 20 years (10–50 years) Wirsing von König (1995), Choi (2016)
Costs (2014 USD)
Cw vaccine wastage rate 5% (0–15%) Brazil data
Cmp maternal vaccine price per dose 9.55 (5.00–15.00) Brazil data
Ccp child vaccine price per dose 2.71 Brazil data
Ccd child vaccine delivery cost per dose 7.60 (SE: 0.50) Brazil data
Cd death-related cost per case See Appendix 6 Brazil data
Ci inpatient cost per case See Appendix 6 Brazil data
Co outpatient cost per case See Appendix 6 Brazil data
S.-Y. Kim et al. Vaccine 39 (2021) 147–157Our model assumed that approximately 50% of all pertussis infec-
tions would be symptomatic [9,10].
Contact rates between age groups were not available for Brazil
and were estimated based on the Polish POLYMOD contact matrix
[11], which, of all the POLYMOD matrices, most closely resembled
Brazilian contact patterns. The rates were adjusted by the ratio of
Brazilian to Polish household size. In addition, we made the matrix
symmetrical (i.e., individuals from two different age groups have
the same contact rates regardless of which group initiates the con-
tact). We then aggregated the age groups in the matrix into three
age groups (<1, 1-9y, and 10+) and defined a multiplier for each
group to allow the age-group-specific rates to vary in the model-
fitting process so that we could identify the best-fitting rates.
Finally, each age group had a different transmission probability
per contact (see Appendix 3 for more details about the contact
rates and transmission probabilities per contact for age groups).
We initially used administrative data on infant vaccination cov-
erage. Administrative data are generally known to overestimate
true vaccine coverage, but are thought to be sufficiently accurate.
The dynamic model showed that they were not, projecting that,
at administrative coverage levels, pertussis would be eliminated
in Brazil in six years, when instead incidence has increased [12].
For more accurate coverage data, we turned to two national vac-
cine coverage surveys conducted in Brazil in 2007 and 1996. The
coverages reported for DTP1, DTP2, and DTP3 are 90%, 79%, and
61% for the 2007 survey data and 94%, 88%, and 74% for the 1996
survey (Appendix 4). Maternal TdaP administrative vaccination
coverage was 10.9%, 48.4%, and 33.8%, respectively, for each year
in 2014–2016. For the base-case analysis, we assumed that cover-
age would linearly increase to a maximum of 70% from 2017 to
2030.
For infant wP vaccine effectiveness, we used 68%, 92%, 99%, for
doses 1, 2, and 3, based on the literature [13]. For maternal aP vac-
cine, we assumed 91% effectiveness for the first three months of
infancy, also based on the literature (Appendix 5).149Appendix 6 describes the cost data used for our analysis, includ-
ing vaccine prices and costs of hospital and outpatient care for per-
tussis. We assumed a 5% vaccine wastage rate for both infant and
maternal vaccines. Maternal vaccine delivery cost was assumed
to be zero, since, in Brazil, TdaP replaced the Td vaccine that was
already being administered to pregnant women. The cost of rou-
tine delivery of infant wP vaccination was estimated to be $2.71/-
dose based on a primary national immunization costing study
conducted in Brazil in 2013 [14].
2.3. Calibration and selection of the best-fitting model
Some of the model parameters are highly uncertain. We cali-
brated each variant to Brazilian data using the likelihood-based
Akaike Information Criterion (AIC) to select the best-fitting model
and determine the values of the highly uncertain parameters (see
Appendix 7 for details). A total of 13 parameters were considered
to be highly uncertain and were varied from distributions assigned
to the parameters for calibration. The variables included: 6 age-
group multipliers for the contact matrix, 3 age-group multipliers
for the transmission probabilities per contact, 3 age-group report-
ing rates for outpatient cases, and the duration of wP induced
immunity. The calibration target was reported (confirmed) pertus-
sis cases. We used age-group-specific pertussis cases, but to keep
the computational burden reasonable, we defined three aggregated
age groups (<1, 1–9, and 10+ years of age).
The fourth variant of the model (Model 4) was determined to be
excluded from the candidate models since it was realized during
the exploratory parameter search phase for calibration that the
model’s boosting related parameters are highly hypothetical and
uncertain and have a potential to yield biologically less plausible
outcomes (e.g., higher reinfection than primary infection under
certain values of the boosting parameters). Thus, model fitting
was conducted for the first three variants only. After fitting each
model to the age-group-specific data over the period 1999–2016,
Fig. 1. Schematic of the best-fitting model (SIRS2I2). The model assumes that both
vaccine-induced and naturally-acquired immunity wane and repeat infection has a
lower reporting rate than primary infection. Brief descriptions of each symbol in the
schematic follow: S: Susceptible population. I: Infected and infectious population.
R: Recovered and immune population from the infection. S2: Population with
waning immunity from V or R compartments. I2: Population with secondary
infection from S2. Vm: Effectively immunized by maternal vaccination. V1: Effec-
tively immunized by the 1st dose of child vaccination. V2: Effectively immunized by
the 2nd dose of child vaccination. V3: Effectively immunized by the 3rd dose of
child vaccination. wi: Proportion moving to protected compartments after vacci-
nation (considering both primary vaccine failure and vaccine efficacy). vi: Propor-
tion of individuals to be vaccinated (vaccine coverage). rV: Waning rate of wP
vaccine-induced immunity. rM: Waning rate of aP vaccine-induced immunity. rR:
Waning rate of natural infection-induced immunity. k: Force of infection. c:
Recovery rate.
S.-Y. Kim et al. Vaccine 39 (2021) 147–157we calculated AIC scores and selected the best fitting model based
on the lowest AIC score.
2.4. Strategies
The best-fitting calibrated model is used to compare strategies
over the period 2017–2030: (1) routine infant wP vaccination
alone (administered at 2, 4, and 6 months); and (2) maternal aP
immunization (using Tdap) plus routine infant wP vaccination.
The latter strategy was based on the assumption that maternal
aP immunization on top of moderate coverage would avert over
90% of infections and deaths.
2.5. Model outcomes
The model was used to project the numbers of pertussis cases
(with and without adjustment for reporting rate), outpatient cases,
hospitalizations, deaths, and DALYs due to pertussis over the time
horizon 2017–2030. The model also estimated costs associated
with outpatient visits, hospitalizations, and deaths due to pertus-
sis. Both health and cost outcomes were discounted at 3%, and
costs were expressed in 2014 US dollars.
2.6. Cost-effectiveness
For the base-case analysis, the model calculates incremental
cost-effectiveness ratios (ICERs) for adding maternal aP immuniza-
tion to infant wP vaccination. The ICER is expressed in terms of
incremental cost per DALY averted. We followed the CHEERS (Con-
solidated Health Economic Evaluation Reporting Standards) state-
ment for reporting the results of the cost-effectiveness analysis
(see Appendix 8 for the CHEERS Checklist completed) [15].
2.7. Uncertainty analysis
We conducted one-way sensitivity analyses to examine the
influence of key parameters on the cost-effectiveness results: level
of infant vaccination coverage, maternal aP coverage, aP vaccine
price for maternal immunization, and discount rate. The model
time horizon was extended up to 2100 in sensitivity analysis, to
explore the effects of alternative time periods over which pertussis
vaccination would be provided. We checked the robustness of the
results by repeating the simulations using the 100 best-fitting
parameter sets with the lowest AIC scores.
2.8. Scenarios for low-income countries
The data needed to develop a dynamic transmission model are
scarce or lacking in low-income countries. To explore the cost-
effectiveness of maternal immunization in these settings we
adapted the current model, using available data on vaccination
coverage, costs, and infant mortality, for two low-income countries
– Bangladesh and Nigeria. Both countries are currently vaccinating
infants with an accelerated schedule (6, 10, 14 weeks). Bangladesh
has high coverage [DTP3 coverage at 1 year: 91% from 2011 survey
data] while coverage rates in Nigeria are low [DTP3 coverage at
1 year: 33% from 2008 survey data]. Recently, it has been proposed
to switch from the accelerated schedule to a simplified schedule
(6 weeks, 14 weeks, 9 months). Accordingly, we compared four
strategies for the two countries: 1) infant vaccination with the
accelerated schedule; 2) infant vaccination with the accelerated
schedule plus maternal immunization; 3) infant vaccination with
the simplified schedule; 4) infant vaccination with the simplified
schedule plus maternal immunization.
For infant vaccination coverage, we used Demographic and
Health Survey data from each country, the 2011 survey for Bangla-150desh and the 2008 survey for Nigeria. For maternal aP coverage we
used the percentages of pregnant women with at least one prenatal
visit (ANC1): 78.6% for Bangladesh in 2014 [16] and 65.8% for Nige-
ria in 2013 [17] and assumed that rate held for the projection per-
iod, 2017–2030. Lacking country data on costs, we adjusted all
costs related to vaccination and treatment using the ratio of GDP
per capita between each country and Brazil (a ratio of 0.09 for Ban-
gladesh vs. Brazil and 0.27 for Nigeria vs. Brazil). We assumed that
the pertussis death rate would be higher due to a higher case-
fatality rate (CFR), which might be attributable to lower access to
health services than in Brazil, and modified the pertussis death rate
using the ratio of CFR of each country and Brazil (a ratio of 4.33 for
Bangladesh vs. Brazil and 2.47 for Nigeria vs. Brazil) [18].
We conducted one-way sensitivity analysis for the low-income
country scenarios, varying maternal aP coverage (ANC4, 31.2% for
Bangladesh [16] and 51.1% for Nigeria [17]), maternal aP vaccine
price ($0.50-$5), time horizon, and discount rate.3. Results
3.1. Model fitting
Based on the AIC measure of goodness-of-fit, the third variant of
the model, SIRS2I2, was selected as the best-fitting model, although
the second variant, SIRS, was close and produced similar results
(see Appendix 7 for the details of the calibration). Fig. 1 presents
the schematic of the best-fitting model (SIRS2I2). Fig. 2 compares
the observed data and projected outcomes using the SIRS2I2 model.3.2. Base-case analysis: Brazil
Table 2 shows projected health and cost outcomes, 2017–2030,
under two alternative infant vaccination coverage levels in Brazil
(base-case rates based on 2007 survey data and higher coverage
rates based on 1996 survey data). A majority of pertussis cases
would be outpatient cases and the death rate would be very low.
Yet, as is typically the case, most of the DALY burdens are attribu-
table to pertussis deaths. Assuming infant vaccination coverage at
the level of 2007, total program costs, 2017–2030, for infant vacci-
nation would be $841 million while costs for maternal aP immu-
nization would be $156 million (see Table 2).
Fig. 2. Best-fitting model (SIRS2I2): Observed (reported and confirmed) vs modeled pertussis cases by age group, 1999–2016.
Table 2
Brazil: Costs, health outcomes, and cost-effectiveness, infant vaccination and infant plus maternal vaccination, by infant vaccination coverage.
Model outcomes Infant vaccination coverage
Base Case (2007 survey) Higher (1996 survey)
Infant only Infant + Maternal Infant only Infant + Maternal
Costs (2014 USD) Treatment outpatient 14,440,733 168,719 152,562 77,261
inpatient 70,860,707 789,176 707,118 343,771
death 769,635 8,855 6,909 3,491
all 86,071,076 966,750 866,589 424,523
Vaccination dtp1 298,709,918 304,064,683 311,081,463 311,106,401
dtp2 283,603,047 288,987,747 302,658,962 302,326,162
dtp3 258,355,868 263,033,627 286,431,095 286,072,388
wP vaccine + delivery 840,668,833 856,086,057 900,171,520 899,504,951
aP (vaccine cost only) – 156,304,969 – 156,304,969
all 840,668,833 1,012,391,026 900,171,520 1,055,809,920
Total cost 926,739,910 1,013,357,776 901,038,109 1,056,234,443
Health outcomes Cases outpatient 1,135,030 10,367 9,354 4,687
inpatient 171,006 1,522 1,311 644
death 901 8 6 3
DALYs YLD_outpt 6,060 71 64 33
YLD_inpt 908 10 9 4
YLD_death 5 0 0 0
YLL_death 20,464 238 177 91
DALY_total 27,437 319 251 128
Cost-effectiveness DALYs 27,437 319 251 128
DALYs averted – 27,118 – 123
Costs 926,739,910 1,013,357,776 901,038,109 1,056,234,443
Incremental costs – 86,617,866 – 155,196,334
Cost/DALY – 3,194 – 1,265,552*
* This figure may look different from that calculated using the rounded figures for DALYs averted (i.e., 123 DALYs), and incremental costs ($155,196,334) due to rounding
error.
S.-Y. Kim et al. Vaccine 39 (2021) 147–157The bottom panel of Table 2 shows the cost-effectiveness of
maternal aP immunization for two infant coverage levels. With
moderate coverage, based on the 2007 survey, maternal aP immu-
nization would avert 27,118 DALYs at an incremental cost of about151$86.6 million, costing $3,194 per DALY averted. With higher infant
vaccination coverage, based on the 1996 survey, maternal aP
immunization would avert only 123 DALYs at an additional cost
of ~$155 million, and would cost $1.27 million per DALY averted.
Table 3
Nigeria and Bangladesh: Cost-effectiveness of maternal aP immunization.








coverage = 65.8%; see methods)
proposed simplified
infant schedule
491,214 341,713,566 – –
current accelerated
infant schedule
479,519 11,695 336,084,494 5,629,072 See below
simplified infant
schedule + maternal aP
22,531 456,988 229,159,278 106,925,216 See below
accelerated infant
schedule + maternal aP
17,021 5,509 223,893,852 5,265,426 Cost-saving (i.e., averts more DALYs than the
alternatives and saves money)
Bangladesh (maternal aP
coverage = 78.6%; see methods)
proposed simplified
infant schedule
699 80,653,133 – –
current accelerated
infant schedule
627 73 81,685,180 1,032,047 14,151
simplified infant
schedule + maternal aP
252 374 101,905,88 20,220,707 54,031
accelerated infant
schedule + maternal aP
243 9 102,948,460 1,042,573 116,656
* Strategies for each country are listed in order of DALYs averted, with the strategy that averts the fewest DALYs at the top, the strategy that averts the most DALYs at the
bottom.
S.-Y. Kim et al. Vaccine 39 (2021) 147–1573.3. Uncertainty analysis
Fig. 3 presents one-way sensitivity analysis results for Brazil.
When maternal vaccine price is reduced to $5, about half the
base-case value ($9.55), cost/DALY decreases to $448 and ~
$658,000 under the moderate and high infant coverage levels,
respectively. Cost/DALY increases modestly as the level of maternal
coverage increases.
Cost/DALY is more sensitive to time horizon under high than
moderate infant coverage. For instance, as the time horizon is
extended from 2030 to 2100, cost/DALY under high infant coverage
increases from ~$1.27 million to ~$4.07 million, while it changes
very little under moderate infant coverage (Fig. 3).
Simulations using the 100 best-fitting parameter sets (those
with the lowest AIC scores) produced distributions for the main
outcomes. Fig. 4 shows the distributions of the main health out-
comes (incident cases, pertussis deaths, and DALYs), by strategy
(infant plus maternal vs. infant only), and by level of infant vacci-
nation coverage, along with 95% credible intervals (CIs). Overall,
the plots show a low level of dispersion around the best-fit
simulations.
Fig. 5 presents the distributions of cost/DALY by level of infant
vaccination coverage, using the same 100 best-fitting parameter
sets. The 95% CI of cost/DALY under the base-case (2007) infant
coverage was $2,144-$3,682 and is skewed toward lower values.
The distribution of cost/DALY under the high infant coverage
(1996) had a more symmetric curve, with a 95% CI of $991,272-
$1,482,752.3.4. Nigeria and Bangladesh: Base case and sensitivity analyses
Table 3 provides the results of the scenario analyses developed
for two example low-income countries, Nigeria and Bangladesh.
Nigeria’s infant coverage level is much lower than that of
Bangladesh.
As described, we evaluated four strategies for the two countries.
For Nigeria, with its lower infant vaccination coverage, the acceler-
ated schedule plus maternal aP immunization would be cost-
saving and dominates all other strategies – that is, it saves more
money and lives than any other strategy. For Bangladesh, with
infant vaccination coverage higher even than Brazil’s 1996 cover-
age, the cost of adding maternal aP immunization to the acceler-
ated infant schedule would be high, ~$117,000/DALY averted.152These findings highlight the role of infant vaccination coverage in
determining the cost-effectiveness of maternal aP immunization.
For Nigeria, the sensitivity analysis results were similar to the
base case; for all parameter values examined, the accelerated
schedule plus maternal aP immunization is the cost-saving and
dominant strategy (Table 4). For Bangladesh, the sensitivity analy-
sis results were also similar to the base-case: adding maternal
immunization to either the accelerated or simplified infant sched-
ule would be very expensive per DALY averted (Table 4).
4. Discussion
The dynamic model captures the herd immunity benefits of
infant pertussis (wP) vaccination and suggests that, if policy mak-
ers are willing to spend GDP per capita to avert a DALY, maternal
aP immunization would be cost-effective in Brazil at recent infant
vaccination coverage rates, which have declined from the high
rates achieved in the 1990s. When infant vaccination rates are in
the 90–95% range or above, maternal aP vaccination does not rep-
resent good value, with incremental cost-effectiveness ratios
exceeding $1 million per DALY averted.
These results contrast with an earlier cost-effectiveness analysis
which found maternal aP vaccination to be cost-effective under a
wide range of circumstances. That static state-transition model
did not capture the herd protection benefits of infant coverage
[19], because it did not consider the entire population but focused
on infants only, and did not explicitly consider the fact that only a
small proportion of pertussis diseases are reported through the
surveillance system.
For Brazil, the results were robust in uncertainty analysis. When
infant wP coverage was moderate, maternal aP vaccination
remained cost-effective under a range of assumptions regarding
time horizon. With infant coverage at a high level, longer time
horizons made maternal aP an increasingly inefficient investment,
with cost exceeding $4 million/DALY when the time horizon
extended to 2100. Under high infant vaccination coverage, pertus-
sis would be nearly eliminated by 2030, so that there is little addi-
tional health benefit from maternal immunization after 2030, but
the costs of maternal immunization continue to be incurred, and
thus cost/DALY averted rises.
If it is expected that the current moderate level of infant wP
coverage will continue in Brazil, provision of maternal aP
immunization would be a worthwhile intervention to prevent
pertussis deaths among young infants. Given, however, that the
Fig. 3. Brazil: Cost-effectiveness of maternal immunization under two alternative infant vaccination coverages. One-way sensitivity analysis.
S.-Y. Kim et al. Vaccine 39 (2021) 147–157cost-effectiveness of maternal aP immunization is sensitive to
the level of infant vaccination coverage, our study highlights
the importance of achieving and maintaining high levels of153infant vaccination coverage. To support that achievement, it is
necessary to have accurate information on the level of infant
vaccination coverage [12].
Fig. 4. Uncertainty analysis: distributions of main health outcomes by infant coverage level, using the 100 best-fitting parameter sets. *M + C: maternal plus infant
vaccination strategy; C: infant vaccination only strategy.
Fig. 5. Uncertainty analysis: distributions of ICERs by infant coverage level, using the 100 best-fitting parameter sets.
S.-Y. Kim et al. Vaccine 39 (2021) 147–157Our study has important implications for low-income countries.
Results for two scenarios designed to represent low-income coun-
tries show that maternal immunization could be cost-saving in
countries with low infant vaccination coverage, but very expensive
in countries with high infant vaccination coverage. Our findings
also suggest that different infant vaccination schedules (the cur-
rent accelerated vs. proposed simplified infant schedule) do not154have much impact on this conclusion. These results should be
interpreted with caution since the model used to produce them
was fitted to data from a setting with different demography,
socioeconomic status, and disease epidemiology. We note, how-
ever, that a separate dynamic model, fitted to data for three Brazil-
ian states that vary widely in their sociodemographic
characteristics, identified as best-fitting each state the same model
Table 4
Nigeria and Bangladesh: Results by maternal aP vaccine price, time horizon, and maternal aP vaccine coverage.









$0.5 Nigeria Proposed simplified infant
schedule
491,214 41,713,566 See below
Current accelerated infant
schedule
479,519 11,695 36,084,494 5,629,072 See below
Simplified infant
schedule + maternal aP
22,531 456,988 185,831,203 150,253,291 See below
Accelerated infant
schedule + maternal aP
17,021 5,509 180,565,778 5,265,426 Cost-saving*
Bangladesh Proposed simplified infant
schedule
699 80,653,133 – –
Current accelerated infant
schedule
627 73 81,685,180 1,032,047 14,151
Simplified infant
schedule + maternal aP
252 374 92,948,007 11,262,828 30,095
Accelerated infant
schedule + maternal aP
243 9 93,990,580 1,042,573 116,656
$5 Nigeria Proposed simplified infant
schedule
491,214 341,713,566 See below
Current accelerated infant
schedule
479,519 11,695 336,084,494 5,629,072 See below
Simplified infant
schedule + maternal aP
22,531 456,988 279,569,826 56,514,668 See below
Accelerated infant
schedule + maternal aP
17,021 5,509 274,304,400 5,265,426 Cost-saving*
Bangladesh Proposed simplified infant
schedule
699 80,653,133 – –
Current accelerated infant
schedule
627 73 81,685,180 1,032,047 14,151
Simplified infant
schedule + maternal aP
252 374 204,921,499 123,236,319 weakly
dominated
Accelerated infant
schedule + maternal aP
243 9 205,964,072 1,042,573 323,643
Time horizon
2017–2050 Nigeria Proposed simplified infant
schedule
914,617 628,769,113 See below
Current accelerated infant
schedule
894,333 20,284 618,832,793 9,936,320 See below
Simplified infant
schedule + maternal aP
126,689 767,644 448,627,220 170,205,572 See below
Accelerated infant
schedule + maternal aP
114,019 12,670 438,212,858 10,414,363 Cost-saving*
Bangladesh Proposed simplified infant
schedule
699 147,486,411 – –
Current accelerated infant
schedule
627 73 149,002,790 1,516,379 20,791
Simplified infant
schedule + maternal aP
252 374 186,489,843 37,487,052 100,168
Accelerated infant
schedule + maternal aP
243 9 88,023,363 1,533,520 171,590
2017–2070 Nigeria Proposed simplified infant
schedule
1,145,182 786,834,301 See below
Current accelerated infant
schedule
1,120,201 24,982 774,515,816 12,318,485 See below
Simplified infant
schedule + maternal aP
176,870 943,331 567,685,412 206,830,404 See below
Accelerated infant
schedule + maternal aP
160,926 15,943 554,614,620 13,070,792 Cost-saving*
Bangladesh Proposed simplified infant
schedule
699 184,490,157 – –
Current accelerated infant
schedule
627 73 186,274,900 1,784,743 24,471
Simplified infant
schedule + maternal aP
252 374 233,321,710 47,046,810 125,712
Accelerated infant
schedule + maternal aP
243 9 235,127,254 1,805,544 202,027
2017–2100 Nigeria Proposed simplified infant
schedule
1,312,754 901,914,144 See below
Current accelerated infant
schedule
1,284,354 28,400 887,859,930 14,054,214 See below
Simplified infant
schedule + maternal aP
213,213 1,071,141 654,450,647 233,409,283 See below
(continued on next page)
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schedule + maternal aP
194,917 18,296 639,452,634 14,998,013 Cost-saving*
Bangladesh Proposed simplified infant
schedule
699 211,482,329 – –
Current accelerated infant
schedule
627 73 213,462,827 1,980,499 27,155
Simplified infant
schedule + maternal aP
252 374 267,482,949 54,020,121 144,345
Accelerated infant
schedule + maternal aP
243 9 269,486,919 2,003,970 224,230
Maternal aP coverage
Coverage based on ANC4 in each
country
Nigeria (51.5%) Proposed simplified infant
schedule
491,214 341,713,566 See below
Current accelerated infant
schedule
479,519 11,695 336,084,494 5,629,072 See below
Simplified infant
schedule + maternal aP
135,185 344,334 255,744,259 80,340,235 See below
Accelerated infant
schedule + maternal aP





699 80,653,133 – –
Current accelerated infant
schedule
627 73 81,685,180 1,032,047 14,151
Simplified infant
schedule + maternal aP
411 215 89,080,219 7,395,039 34,346
Accelerated infant
schedule + maternal aP
386 25 90,118,034 1,037,815 41,655
* Averts more DALYs and saves more cost than the alternatives.
S.-Y. Kim et al. Vaccine 39 (2021) 147–157structure identified here, suggesting that the nature of the disease
and its transmission is similar across very different settings [20].
Our study has several limitations. First, due to the uncertainty
about reporting rates and the quality of data from different
sources, we had to make assumptions about some less well-
known aspects of pertussis disease such as the proportion of cases
that are symptomatic. Second, due to the computational burden of
the calibration process, not all of the uncertain parameters (e.g.,
duration of maternal aP immunity and natural immunity) were
varied through the modeling-fitting process. Third, due to the lack
of Brazilian data on age-group-specific contact rates, we had to
borrow a Polish contact matrix from the POLYMOD study con-
ducted in Europe; we adjusted the contact matrix by applying
the ratio of household size of the two countries. Fourth, due to a
lack of incidence and vaccine coverage data for years before
1999, accurate calculations of the initial conditions were limited.
Finally, the model was fitted to a country that uses wP vaccine
for infants and may not apply to countries where infants receive
aP vaccine.
Despite these limitations, our study suggests that a dynamic
transmission model is a useful tool for projecting the potential
health and cost outcomes of maternal aP immunization and gener-
ating evidence for policy formulation. For pathogens that are trans-
mitted across age groups, and where interventions such as infant
vaccination induce herd effects, maternal immunization models
must consider transmission dynamics to produce accurate projec-
tions [21]. To our knowledge, our study is the first to evaluate the
cost-effectiveness of maternal aP immunization in middle- or low-
income countries using a dynamic model. The results suggest that
maternal aP immunization has a role, but only when high levels of
infant vaccination cannot be achieved.Data statement
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